RET and neoplasm: The molecular landscape of PTC is defined by well-characterized driver mutations, predominantly involving alterations in the MAPK signaling pathway, specifically in the BRAF, RAS and RET/PTC genes, which are key contributors to tumor initiation and progression [8,9,10,11].